On October 13, Moderna, Inc. falls 3.06% in Regular Trading, trading at $205.26 per share, with turnover of $157 million.

The move follows continued profit-taking after the company’s October 9 inclusion in the Nasdaq-100, as the passive-fund support effect appears to be fading after the stock’s earlier sharp rally.

Recent market coverage indicated Moderna, Inc. had surged after joining the Nasdaq-100, with enthusiasm also supported by rising commercialization expectations for individualized cancer vaccine intismeran autogene. However, the latest trading session showed that short-term funds were locking in gains. Earlier reports noted the stock had already fallen 6.07% in the prior session after an intraday drop of 3.28%, suggesting the index-inclusion catalyst was being digested even as bullish options positioning and oncology-vaccine expectations had previously strengthened sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)